Mr. Oruc has advised on antitrust issues associated with countless consummated and proposed transactions for private equity and public company clients. He has shepherded transactions through the FTC, DOJ and competition authorities outside of the US. His litigation experience includes single company monopolization cases, allegations of abuse of intellectual property, standard setting activities, foreclosure allegations, as well as successful amnesty applications in cartel investigations.
Representative matters:
- BioDelivery Sciences International, Inc. in its proposed acquisition by Collegium Pharmaceutical for $604 million.
- Ampersand Capital Partners in its sale of Nexelis Group, Inc. to Q2 Solutions, a wholly owned subsidiary of IQVIA, Inc.
- Audacious Inquiry on its agreement to be acquired by PointClickCare Technologies.
- Nimbus Therapeutics in its proposed acquisition by Celgene and Nimbus's related antitrust litigation against Celgene and Bristol Myers Squibb.
- Trillium Therapeutics in its sale to Pfizer for $2.26 billion.
- OneLogin in its acquisition by One Identity LLC, a subsidiary of Quest Software Inc.
- Syndax in its strategic collaboration with Incyte for up to $152 million.
- A non-US company in a grand jury investigation by the DOJ, Antitrust Division.
- Co-counsel for Weyerhaeuser in the seminal monopsonization litigations.*
- Lead counsel for Staples in antitrust litigations and government investigations related to product design and strategy issues surrounding private label ink cartridges compatible with HP-branded printers.*
- Lead counsel for Ericsson in a Sherman Act challenge brought by “positioning” technology company whose technology was excluded from the 4G standard.*
- Lead antitrust counsel to the standard-setting organization through the format war between HD DVD and Blu-ray technologies.*
- Represented MasterCard in numerous antitrust litigations against the DOJ, American Express, Discover and Visa.*
*Denotes experience prior to joining Goodwin.
